Publication: Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria
dc.contributor.author | C. Luxemburger | en_US |
dc.contributor.author | F. O. Ter Kuile | en_US |
dc.contributor.author | F. Nosten | en_US |
dc.contributor.author | G. Dolan | en_US |
dc.contributor.author | J. H. Bradol | en_US |
dc.contributor.author | L. Phaipun | en_US |
dc.contributor.author | T. Chong-Suphajaisiddhi | en_US |
dc.contributor.author | N. J. White | en_US |
dc.contributor.other | Shoklo Malaria Research Unit | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | University of Amsterdam | en_US |
dc.contributor.other | Nuffield Department of Clinical Neurosciences | en_US |
dc.date.accessioned | 2018-02-27T04:26:52Z | |
dc.date.available | 2018-02-27T04:26:52Z | |
dc.date.issued | 1994-01-01 | en_US |
dc.description.abstract | The therapeutic efficacy and toxicity of a combination of low dose mefloquine (15 mg/kg) plus artesunate 10 mg/kg in one day (MA) was compared with the currently used regimen of high dose mefloquine (25 mg/kg) (MQ) in 552 patients with uncomplicated falciparum malaria in an area of multi-drug resistance on the Thai-Burmese border. MA gave faster clinical and parasitological responses and prevented early treatment failure; 15 patients in the MQ group (6%)were early failures ( < 9 d) compared with none receiving MA (P = 0.0001). Overall failure rates by day 28 were 19% in the MA group and 24% in with MQ group (relative risk (RR) = 0.78, 95% confidence interval(CI) 0.54−1.12). In the subgroup of patients who required re-treatment, MA proved significantly more effectivethan MQ; failure rates were 25% and 52% respectively (RR = 0.49, 95% CI = 0.29−0.83). Treatment failures were associated with mefloquine treatment in the previous month (RR = 1.72, 95% CI = 1.09−2.70) and diarrhoea (RR = 1.55, 95% CI = 1.05−2.28). Gastrointestinal side-effects and dizziness were more likely in the MQ group. There was no evident adverse effect as sociated with artesunate. A single day's treatment with artesunate augments the antimalarial efficacy of mefloquine. © 1994 Oxford University Press. | en_US |
dc.identifier.citation | Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.88, No.2 (1994), 213-217 | en_US |
dc.identifier.doi | 10.1016/0035-9203(94)90303-4 | en_US |
dc.identifier.issn | 18783503 | en_US |
dc.identifier.issn | 00359203 | en_US |
dc.identifier.other | 2-s2.0-0028182993 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/9601 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0028182993&origin=inward | en_US |
dc.subject | Immunology and Microbiology | en_US |
dc.subject | Medicine | en_US |
dc.title | Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0028182993&origin=inward | en_US |